Novavax to Participate in BofA Securities 2026 Health Care Conference

Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2026 Health Care Conference.
Nature

In vivo molecular target assessment of matrix metalloproteinase inhibition

A number of different matrix metalloproteinase (MMP) inhibitors have been developed as cytostatic and anti-angiogenic agents and are currently in clinical testing. One major hurdle in assessing the ...

Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights

Total revenue of $140 million in the first quarter of 2026 Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious ...
Nature

Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases

Historically, testing matrix metalloproteinase inhibitors (MMPIs) for the therapy of invasive or metastatic cancers has not yielded the expected beneficial results, but has had a positive effect on ...